prednisolone has been researched along with Myxedema in 21 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Myxedema: A condition characterized by a dry, waxy type of swelling (EDEMA) with abnormal deposits of MUCOPOLYSACCHARIDES in the SKIN and other tissues. It is caused by a deficiency of THYROID HORMONES. The skin becomes puffy around the eyes and on the cheeks. The face is dull and expressionless with thickened nose and lips.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 39-year-old woman with primary myxedema, who had the potent activities of thyrotropin-binding inhibitory immunoglobulins (TBII) and thyroid-stimulation blocking antibodies (TSBAb), developed aortitis syndrome about 6 months after the initiation of L-thyroxine (L-T4) supplementation." | 7.68 | Disappearance of thyroid-stimulation blocking antibody by glucocorticoid therapy in a patient with primary myxedema who developed aortitis syndrome during L-thyroxine supplementation. ( Kouchi, T; Mashiba, H; Mitani, Y; Shigemasa, C; Taniguchi, S, 1990) |
| "Scleromyxedema is a rare mucinous disease without thyroid dysfunction, associated with a monoclonal gammopathy." | 5.31 | [Initial scleromyxedema. Successful treatment with melphalan]. ( Meurer, M; Schubert, K; Stein, A, 2002) |
| "A 39-year-old woman with primary myxedema, who had the potent activities of thyrotropin-binding inhibitory immunoglobulins (TBII) and thyroid-stimulation blocking antibodies (TSBAb), developed aortitis syndrome about 6 months after the initiation of L-thyroxine (L-T4) supplementation." | 3.68 | Disappearance of thyroid-stimulation blocking antibody by glucocorticoid therapy in a patient with primary myxedema who developed aortitis syndrome during L-thyroxine supplementation. ( Kouchi, T; Mashiba, H; Mitani, Y; Shigemasa, C; Taniguchi, S, 1990) |
| " The ratio of 3-methylhistidine:creatinine excretion, a measure of the fractional catabolic rate of myofibrillar protein was increased in severe injury, thyrotoxicosis, neoplastic disease, prednisolone administration, and sometimes Duchenne muscular dystrophy." | 3.66 | Clinical usefulness of urinary 3-methylhistidine excretion in indicating muscle protein breakdown. ( Bacon, S; Carter, A; Elia, M; Smith, R; Winearls, CG, 1981) |
| "A 66-year-old man presented with Graves' disease and widespread localized myxedema." | 2.39 | Localized myxedema, associated with increased serum hyaluronic acid, and response to steroid pulse therapy. ( Goto, Y; Kohda, H; Mizuta, T; Ohtsuka, Y; Ozaki, I; Sakai, T; Setoguchi, Y; Yamamoto, K, 1995) |
| "Scleromyxedema is a rare mucinous disease without thyroid dysfunction, associated with a monoclonal gammopathy." | 1.31 | [Initial scleromyxedema. Successful treatment with melphalan]. ( Meurer, M; Schubert, K; Stein, A, 2002) |
| "Scleromyxedema is the consequence of a dermal infiltration by mucine, commonly associated with a monoclonal gammapathy of unknown significance." | 1.31 | [Cutaneo-systemic papulosclerotic mucinosis (scleromyxedema): remission after extracorporeal photochemotherapy and corticoid bolus]. ( Achin, R; Bacin, F; Beyvin, AJ; D'Incan, M; Demeocq, F; Franck, F; Kanold, J; Souteyrand, P, 2001) |
| "Scleromyxedema is an uncommon disease of unclear etiology." | 1.31 | [Extracorporeal photopheresis--treatment option in scleromyxedema?]. ( Bock, M; Durani, BK; Näher, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (42.86) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Perepelova, MA | 1 |
| Zaitseva, EL | 1 |
| Bessmertnaya, EG | 1 |
| Grusha, YO | 1 |
| Sviridenko, NY | 1 |
| Galstyan, GR | 1 |
| Shirai, K | 1 |
| Ito, T | 1 |
| Mitsuhashi, Y | 1 |
| Tsuboi, R | 1 |
| Sendhil Kumaran, M | 1 |
| Dutta, P | 1 |
| Sakia, U | 1 |
| Dogra, S | 1 |
| Schubert, K | 1 |
| Stein, A | 1 |
| Meurer, M | 1 |
| Lin, YC | 1 |
| Wang, HC | 1 |
| Shen, JL | 1 |
| Elia, M | 1 |
| Carter, A | 1 |
| Bacon, S | 1 |
| Winearls, CG | 1 |
| Smith, R | 1 |
| Ohtsuka, Y | 1 |
| Yamamoto, K | 1 |
| Goto, Y | 1 |
| Mizuta, T | 1 |
| Ozaki, I | 1 |
| Setoguchi, Y | 1 |
| Kohda, H | 1 |
| Sakai, T | 1 |
| Kitamura, Y | 1 |
| Yoshida, T | 1 |
| Tsusaka, N | 1 |
| Akizuki, M | 1 |
| Handa, M | 1 |
| Ikeda, Y | 1 |
| Momotani, M | 1 |
| Ito, K | 1 |
| Tsushima, T | 1 |
| D'Incan, M | 1 |
| Franck, F | 1 |
| Kanold, J | 1 |
| Bacin, F | 1 |
| Achin, R | 1 |
| Beyvin, AJ | 1 |
| Demeocq, F | 1 |
| Souteyrand, P | 1 |
| Durani, BK | 1 |
| Bock, M | 1 |
| Näher, H | 1 |
| Shigemasa, C | 1 |
| Kouchi, T | 1 |
| Taniguchi, S | 1 |
| Mitani, Y | 1 |
| Mashiba, H | 1 |
| Keong, CH | 1 |
| Asaka, Y | 1 |
| Fukuro, S | 1 |
| Miyamoto, C | 1 |
| Katsumata, M | 1 |
| Iino, Y | 1 |
| Komiya, T | 1 |
| Göring, HD | 1 |
| Ziemer, A | 1 |
| Benoit, FL | 1 |
| Greenspan, FS | 1 |
| Pickardt, CR | 1 |
| Boergen, KP | 1 |
| Heinze, HG | 1 |
| Murase, T | 1 |
| Mukoyama, A | 1 |
| Osawa, N | 1 |
| Nagataki, S | 1 |
| Yamaji, T | 1 |
| Roberts, CI | 1 |
| Zeltner, G | 1 |
| Fekete, T | 1 |
| Panyi, M | 1 |
| Hausmann, W | 1 |
| Potter, B | 1 |
3 reviews available for prednisolone and Myxedema
| Article | Year |
|---|---|
Scleromyxedema: An experience using treatment with systemic corticosteroid and review of the published work.
Topics: Adult; Glucocorticoids; Humans; Male; Myxedema; Prednisolone; Skin Diseases | 2006 |
Localized myxedema, associated with increased serum hyaluronic acid, and response to steroid pulse therapy.
Topics: Administration, Oral; Aged; Drug Therapy, Combination; Graves Disease; Humans; Hyaluronic Acid; Inje | 1995 |
[Emergency drug therapy of thyroid disease].
Topics: Agranulocytosis; Antithyroid Agents; Emergencies; Humans; Hydrocortisone; Iodine; Myxedema; Predniso | 1995 |
18 other studies available for prednisolone and Myxedema
| Article | Year |
|---|---|
[An integrated approach to the treatment of pretibial myxedema based on pulse therapy with prednisolone and electrical neuromyostimulation (FREMS-therapy) in a patient with Graves' disease and thyroid eye disease].
Topics: Graves Disease; Graves Ophthalmopathy; Humans; Myxedema; Patients; Prednisolone | 2023 |
Dramatic effect of low-dose oral steroid on elephantiasic pretibial myxedema.
Topics: Adult; Elephantiasis; Glucocorticoids; Humans; Leg Dermatoses; Male; Myxedema; Prednisolone | 2014 |
Long-term follow-up and epidemiological trends in patients with pretibial myxedema: an 11-year study from a tertiary care center in northern India.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Clobetasol; Drug Therapy, Combination; | 2015 |
[Initial scleromyxedema. Successful treatment with melphalan].
Topics: Aged; Biopsy; Diagnosis, Differential; Drug Therapy, Combination; Facial Dermatoses; Female; Humans; | 2002 |
Clinical usefulness of urinary 3-methylhistidine excretion in indicating muscle protein breakdown.
Topics: Adolescent; Adult; Aged; Child; Creatinine; Diabetes Mellitus; Diet; Female; Hip Joint; Histidine; H | 1981 |
[Case of EMO syndrome treated with plasma exchange].
Topics: Bone Diseases; Exophthalmos; Humans; Male; Middle Aged; Myxedema; Osteoarthropathy, Primary Hypertro | 1994 |
[Cutaneo-systemic papulosclerotic mucinosis (scleromyxedema): remission after extracorporeal photochemotherapy and corticoid bolus].
Topics: Combined Modality Therapy; Female; Glucocorticoids; Humans; Middle Aged; Myxedema; Photopheresis; Pr | 2001 |
[Extracorporeal photopheresis--treatment option in scleromyxedema?].
Topics: Administration, Oral; Anti-Inflammatory Agents; Cyclophosphamide; Drug Therapy, Combination; Female; | 2001 |
Disappearance of thyroid-stimulation blocking antibody by glucocorticoid therapy in a patient with primary myxedema who developed aortitis syndrome during L-thyroxine supplementation.
Topics: Adult; Aortic Arch Syndromes; Autoantibodies; Female; Humans; Immunoglobulins, Thyroid-Stimulating; | 1990 |
Successful treatment of scleromyxedema with plasmapheresis and immunosuppression.
Topics: Cyclophosphamide; Fibroblasts; Humans; Immunosuppression Therapy; Male; Middle Aged; Myxedema; Plasm | 1990 |
[Immunopathogenetic, endocrinologic and therapeutic problems of EMO syndrome. Observations based on a case report].
Topics: Autoantibodies; Azathioprine; Female; Graves Disease; Humans; Leg Dermatoses; Microsomes; Middle Age | 1989 |
Corticoid therapy for pretibial myxedema. Observations on the long-acting thyroid stimulator.
Topics: Adrenocorticotropic Hormone; Adult; Female; Fluocinolone Acetonide; Humans; Hyperthyroidism; Long-Ac | 1967 |
[Endocrine ophthalmopathy].
Topics: Endocrine System Diseases; Eye Diseases; Eye Manifestations; Graves Disease; Humans; Hyperthyroidism | 1974 |
A survival case of myxedema coma of pituitary origin.
Topics: Administration, Oral; Adult; Coma; Female; Glucose; Humans; Hypopituitarism; Injections, Intravenous | 1973 |
Mixed monoclonal-polyclonal gammopathy.
Topics: Adult; Antibodies, Antinuclear; Autoimmune Diseases; Blood Protein Electrophoresis; Female; Hepatiti | 1969 |
[Successful treatment of myxedematous coma].
Topics: Aged; Coma; Female; Humans; Myxedema; Prednisolone; Respiration, Artificial; Thyronines | 1972 |
Myxoedema crisis.
Topics: Adrenal Glands; Aged; Blood Pressure; Body Temperature; Coma; Female; Humans; Hydrocortisone; Male; | 1970 |
Autosensitivity erythema?
Topics: Adenocarcinoma, Papillary; Autoimmune Diseases; Blood Cell Count; Blood Platelets; Erythema; Female; | 1968 |